Physician profile
Sameeksha Prem
NPI 1366985160
$1,464.21
in general payments reported to CMS, 2019-2025
23 companies · $28.67 in 2025
The $28.67 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $535 · 2023: $396 · 2024: $238 · 2025: $28.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.49 |
| Education | $273.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $283.21 | 2023 | Xtandi |
| Amgen INC. | $220.65 | 2022-2023 | Xgeva, Nplate |
| Incyte Corporation | $164.96 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $124.63 | 2024 | Invega Trinza, Invega Sustenna |
| Abbvie INC. | $101.70 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.80 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $70.00 | 2021-2022 | |
| Gilead Sciences, INC. | $45.26 | 2022 | |
| Genentech USA, INC. | $41.46 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $39.30 | 2021-2023 | Epkinly, Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $34.89 | 2021 | |
| Janssen Biotech, INC. | $33.17 | 2021-2023 | Erleada |
| Karyopharm Therapeutics INC. | $28.76 | 2022 | |
| Aveo Pharmaceuticals, INC. | $27.44 | 2022 | |
| Boston Scientific Corporation | $26.49 | 2023 | Wavewriter Alpha Prime 16 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $24.82 | 2024 | Clonoseq |
| Novocure INC. | $22.07 | 2021 | |
| Celgene Corporation | $21.36 | 2023 | Pomalyst |
| Novartis Pharmaceuticals Corporation | $19.79 | 2021 | |
| Acceleron Pharma, INC. | $16.99 | 2021 | |
| Sobi, INC | $15.70 | 2024 | |
| Servier Pharmaceuticals LLC | $15.15 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameeksha Prem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.